drugset / Trial / NCT01960140

A Study of Baricitinib and Simvastatin in Healthy Participants

NCT01960140

Phase 1 Completed 40 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purposes of this study are to determine the effects of baricitinib on the time it takes to remove simvastatin from the body and to look at how well-tolerated and safe baricitinib is when given alone and in combination with simvastatin. Side effects will be documented. The study will last approximately 7 days from the first dose to the end of the study (not including screening or follow-up).

Timeline

Start
2013-10
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 10 mg Oral
Subject Simvastatin Small molecule 40 mg Oral

Indications

No indication recorded.